1.
Org Biomol Chem
; 11(22): 3706-32, 2013 Jun 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23624850
RESUMO
We herein report on the pharmacophore determination of the ERK docking domain inhibitor (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione, which has led to the discovery of compounds with greater selectivities for inhibiting the proliferation of melanoma cells containing active ERK signaling.